



## AGENDA Forum and Webinar

Saturday, September 7, 2024  
Fairmont Century Plaza, Los Angeles  
9:00 am PST

### Zoom Webinar Registration Link:

[https://us02web.zoom.us/webinar/register/WN\\_FD3UVnoIREG5jGyZDjYfew](https://us02web.zoom.us/webinar/register/WN_FD3UVnoIREG5jGyZDjYfew)

- I. **Welcome:** Nancy Davis, Founder and President of CAN
- II. **Moderator and Introduction of Panel:** Kurt Rasmussen, Ph.D., CSO Delix Therapeutics and Scientific Advisory Board Chair for Cure Addiction Now
- III. **Living with substance use disorder:** Lisa Vidal, Guest Panelist and Advocate
- IV. **Topics:**
  1. **Need for Innovation in the Treatment of Substance Use Disorders**  
Kelly E. Dunn, Ph.D., Johns Hopkins University School of Medicine
  2. **Focused Ultrasound Neuromodulation as an Adjunctive Treatment Strategy for SUD**  
James J. Mahoney, III, Ph.D., Rockefeller Neuroscience Institute, WVU Medicine
  3. **Ketamine in the ED as a way to help treat precipitated and/or unmanaged opioid withdrawal**  
Andrew A Herring, MD, PI Bridge Center, Public Health Institute
  4. **Semaglutide (Ozempic) as a Potential Treatment for Alcohol Use Disorder**  
Christian Hendershot, Ph.D., USC
  5. **Tezampanel: A new medication for opiate withdrawal**  
Christopher Toombs, Ph.D., DABT, co-Founder and Chief Scientific Officer for Proniras Corporation
  6. **Cimetidine as a potential therapeutic to reduce fentanyl withdrawal severity**  
Cassandra D. Gipson-Reichardt, Ph.D., University of Kentucky
  7. **Scientists are Creating More Paths to Success for Individuals with Substance Use Disorders**  
Cecilia Bergeria, Ph.D., Johns Hopkins University School of Medicine
  8. **Vaccines and monoclonal antibodies as treatments for opioid use disorder and opioid overdose**  
Sandra Comer, Ph.D., Columbia University Irving Medical Center
  9. **Evaluating suvorexant for persons who use both opioids and cocaine: Feasibility and lessons learned**  
Jennifer Ellis, Ph.D., Johns Hopkins School of Medicine
  10. **Public Health Policy and SUD**  
Adam Kaplin, M.D., Ph.D., CSO MyMD Pharmaceuticals
- V. **Conclusion and thank you by Nancy Davis**